Inmune Bio (INMB) Receivables - Net (2021 - 2026)
Inmune Bio (INMB) posted Receivables - Net of $479000.0 for Q1 2026, down 88.82% sequentially from $4.3 million in Q4 2025, and down 62.67% YoY from $1.3 million in Q1 2025.
Inmune Bio (INMB) Receivables - Net (2021 - 2026) Analysis & Trends
Inmune Bio has reported Receivables - Net for 6 years, with the latest figure at $479000.0 in Q1 2026.
- Quarterly Receivables - Net fell 62.67% year-over-year to $479000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $479000.0 (down 62.67% YoY) and the FY2025 annual result came in at $4.3 million, up 262.74% from the prior year.
- Receivables - Net fell to $479000.0 in Q1 2026 per INMB's latest filing, from $4.3 million in the prior quarter.
- Over five years, Receivables - Net peaked at $4.3 million in Q4 2025 and troughed at $18000.0 in Q4 2022.
- A 5-year average of $1.3 million and a median of $1.2 million in 2024 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2022 and 2023: Receivables - Net slumped 94.0% in 2022, then soared 10483.33% in 2023.
- Over 5 years, Receivables - Net stood at $18000.0 in 2022, then jumped by 10483.33% to $1.9 million in 2023, then plunged by 38.01% to $1.2 million in 2024, then soared by 262.74% to $4.3 million in 2025, then sank by 88.82% to $479000.0 in 2026.
- According to Business Quant data, Receivables - Net over the past three periods registered $479000.0, $4.3 million, and $1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.41 Mn |
| Jun 30, 2026 | 4.41 Mn |
| Mar 31, 2026 | 479,000.00 |
| Mar 31, 2026 | 479,000.00 |
| Dec 31, 2025 | 4.28 Mn |
| Dec 31, 2025 | 4.28 Mn |
| Sep 30, 2025 | 1.70 Mn |
| Sep 30, 2025 | 1.70 Mn |
| Jun 30, 2025 | 1.61 Mn |
| Jun 30, 2025 | 1.61 Mn |
| Mar 31, 2025 | 1.28 Mn |
| Mar 31, 2025 | 1.28 Mn |
| Dec 31, 2024 | 1.18 Mn |
| Dec 31, 2024 | 1.18 Mn |
| Sep 30, 2024 | 1.11 Mn |
| Sep 30, 2024 | 1.11 Mn |
| Jun 30, 2024 | 3.14 Mn |
| Jun 30, 2024 | 3.14 Mn |
| Dec 31, 2023 | 1.91 Mn |
| Dec 31, 2023 | 1.91 Mn |